What if you could assess multiple cellular parameters faster, with fewer cells, and using lower amounts of reagents?
What if screening for the best antibody took less than half the time and you ended up with more than twice as much information?
What if you could expand phenotypic screening to suspension cells at a fraction of the cost—and time—of a high-end high-content imaging system?
What if you could meet the varying needs of your end users while providing the best service?
The iQue Screener will scale our project throughput in a way that would have been impossible using our current methods.
Matt Johnson, PhD, CTO Avacta Life Sciences